As increasing evidence links the PRR/TBK1/IRF3 axis to autoimmune disease (including systemic lupus erythematosus [SLE]) (5), vaccine responses (6), and the development of malignancy (7), the identification of regulators of this pathway may reveal novel therapeutic targets. This evidence concerns the gene TBK1 and systemic lupus erythematosus.